Expand NXTC Menu
NXTC MENU

NXTC Stock Posts


NXTC #Nextcure stock increases 44.9% after hours.

After Hours Gainer

NXTC Nextcure5.26+0.06+1.2%

After Hours:7.62+2.36 (+44.9%)

Preclinical Data Demonstrate Anti-Siglec-15 Treatment Improves Bone Microarchitecture and Reduces Fracture Incidence in Mice with Moderate-to-Severe Osteogenesis Imperfecta

Globe NewswireThu, 24-Jul 4:05 PM
NXTC #Nextcure stock increases 60.0% after hours.

After Hours Gainer

NXTC Nextcure5.13-0.07-1.4%

After Hours:8.21+3.08 (+60.0%)

Preclinical Data Demonstrate Anti-Siglec-15 Treatment Improves Bone Microarchitecture and Reduces Fracture Incidence in Mice with Moderate-to-Severe Osteogenesis Imperfecta

Globe NewswireThu, 24-Jul 4:05 PM
Unusual Option Volume

NXTC Nextcure4.51+0.13 (+3.0%)

Nextcure trades 2,285 contracts. The highest volume is in the 16-Dec-22 5 puts, which is -10.9% below the current price. News: Dr. Brahm Segal appointed to NextCure Scientific Advisory Board; NextCure and Roswell Park Shared Nonclinical Data on the Impact of NC410 Blockade on Neutrophil-mediated T Cell Suppression at the 24th Translational Research Cancer Centers Consortium Annual Meeting
View Details...
$NXTC 17-Jun-22 Straddle Implies a ±5.3% move. Jun 15 JMP Securities Life Sciences Conference
NXTC #Nextcure stock declines -10.8% in premarket,

Premarket Decliner

NXTC Nextcure12.33+0.18+1.5%

Premarket:11.00-1.33 (-10.8%)

NextCure Provides Updates on NC318 Clinical Program

Globe NewswireThu, 17-Dec 7:05 AM
NXTC #NextcureInc. stock declines -22.3% in premarket,

Premarket Decliner

NXTC Nextcure Inc.17.88-0.30-1.7%

Premarket:13.90-3.98 (-22.3%)

NextCure Provides an Interim Update of the Phase 2 Portion of the NC318 Monotherapy Phase 1/2 Trial and Announces Departure of Chief Medical Officer

Globe NewswireMon, 13-Jul 6:06 AM
Load Earlier Posts
Market Data Delayed 15 Minutes